T Ohtsu

Summary

Affiliation: National Cancer Center
Country: Japan

Publications

  1. ncbi Prognostic analysis and a new risk model for Hodgkin lymphoma in Japan
    Kuniaki Itoh
    Division of Oncology and Hematology, National Cancer Center Hospital East, 6 5 1 Kashiwanoha, Kashiwa, Chiba 277 8577, Japan
    Int J Hematol 91:446-55. 2010
  2. ncbi Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9505
    K Itoh
    Division of Hematology and Oncology, National Cancer Center Hospital East, Kashiwa, Japan
    Ann Oncol 13:1347-55. 2002
  3. ncbi Dose-escalation study of CHOP with or without prophylactic G-CSF in aggressive non-Hodgkin's lymphoma
    K Itoh
    Division of Hematology and Oncology, National Cancer Center Hospital East, Kashiwa, Chiha, Japan
    Ann Oncol 11:1241-7. 2000
  4. ncbi Study of dose escalation and sequence switching of administration of the combination of docetaxel and doxorubicin in advanced breast cancer
    K Itoh
    Division of Oncology and Hematology, National Cancer Center Hospital East, Kashiwa, Japan
    Clin Cancer Res 6:4082-90. 2000
  5. ncbi Randomized comparison of mobilization kinetics of circulating CD34+ cells between biweekly CHOP and dose-escalated CHOP with the prophylactic use of lenograstim (glycosylated rHuG-CSF) in aggressive non-Hodgkin's lymphoma. The lenograstim/Lymphoma Study G
    K Itoh
    Division of Hematology and Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
    Leuk Lymphoma 38:521-32. 2000
  6. ncbi Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study
    T Igarashi
    Hematology and Oncology Division, National Cancer Center Hospital East, Kashiwa, Tokyo, Japan
    Ann Oncol 13:928-43. 2002
  7. ncbi Re-treatment of relapsed indolent B-cell lymphoma with rituximab
    T Igarashi
    Hematology and Oncology, National Cancer Center Hospital East, Kashiwa, Japan
    Int J Hematol 73:213-21. 2001
  8. ncbi Indirect-response model for the time course of leukopenia with anticancer drugs
    H Minami
    National Cancer Center Hospital East, Kashiwa, Japan
    Clin Pharmacol Ther 64:511-21. 1998
  9. ncbi Phase I study of intravenous PSC-833 and doxorubicin: reversal of multidrug resistance
    H Minami
    Division of Oncology Hematology, Department of Medicine, National Cancer Center Hospital East, Kashiwa, Chiba 277 8577, Japan
    Jpn J Cancer Res 92:220-30. 2001
  10. ncbi Unexpected hepatotoxicities in patients with non-Hodgkin's lymphoma treated with irinotecan (CPT-11) and etoposide
    T Ohtsu
    Department of Medicine, National Cancer Center Hospital East, Chiba, Japan
    Jpn J Clin Oncol 28:502-6. 1998

Detail Information

Publications16

  1. ncbi Prognostic analysis and a new risk model for Hodgkin lymphoma in Japan
    Kuniaki Itoh
    Division of Oncology and Hematology, National Cancer Center Hospital East, 6 5 1 Kashiwanoha, Kashiwa, Chiba 277 8577, Japan
    Int J Hematol 91:446-55. 2010
    ..7% in the low-risk group (no adverse factor), 87.9% in the intermediate-risk group (1 adverse factor) and 73.3% in the high-risk group (2 adverse factors). This simple prognostic model for HL warrants further validation studies...
  2. ncbi Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9505
    K Itoh
    Division of Hematology and Oncology, National Cancer Center Hospital East, Kashiwa, Japan
    Ann Oncol 13:1347-55. 2002
    ..The aim of the present study was to explore a suitable therapeutic-intensified regimen for the treatment of aggressive NHL...
  3. ncbi Dose-escalation study of CHOP with or without prophylactic G-CSF in aggressive non-Hodgkin's lymphoma
    K Itoh
    Division of Hematology and Oncology, National Cancer Center Hospital East, Kashiwa, Chiha, Japan
    Ann Oncol 11:1241-7. 2000
    ....
  4. ncbi Study of dose escalation and sequence switching of administration of the combination of docetaxel and doxorubicin in advanced breast cancer
    K Itoh
    Division of Oncology and Hematology, National Cancer Center Hospital East, Kashiwa, Japan
    Clin Cancer Res 6:4082-90. 2000
    ..The sequence of 50 mg/m2 doxorubicin followed by 60 mg/m2 docetaxel is recommended for subsequent clinical trials for practical reasons...
  5. ncbi Randomized comparison of mobilization kinetics of circulating CD34+ cells between biweekly CHOP and dose-escalated CHOP with the prophylactic use of lenograstim (glycosylated rHuG-CSF) in aggressive non-Hodgkin's lymphoma. The lenograstim/Lymphoma Study G
    K Itoh
    Division of Hematology and Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
    Leuk Lymphoma 38:521-32. 2000
    ..The mobilization kinetics of circulating progenitor cells in patients with aggressive NHL is dependent on the dosage and schedule of CHOP...
  6. ncbi Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study
    T Igarashi
    Hematology and Oncology Division, National Cancer Center Hospital East, Kashiwa, Tokyo, Japan
    Ann Oncol 13:928-43. 2002
    ..01). CONCLUSIONS: Several prognostic factors and serum rituximab levels are useful for predicting the toxicity and efficacy of rituximab monotherapy...
  7. ncbi Re-treatment of relapsed indolent B-cell lymphoma with rituximab
    T Igarashi
    Hematology and Oncology, National Cancer Center Hospital East, Kashiwa, Japan
    Int J Hematol 73:213-21. 2001
    ..In conclusion, rituximab re-treatment was well tolerated, and it may produce a prolonged PFS in some patients with indolent B-cell NHL who showed initial response to rituximab...
  8. ncbi Indirect-response model for the time course of leukopenia with anticancer drugs
    H Minami
    National Cancer Center Hospital East, Kashiwa, Japan
    Clin Pharmacol Ther 64:511-21. 1998
    ..In this study, a pharmacodynamic model was developed to simulate leukopenia...
  9. ncbi Phase I study of intravenous PSC-833 and doxorubicin: reversal of multidrug resistance
    H Minami
    Division of Oncology Hematology, Department of Medicine, National Cancer Center Hospital East, Kashiwa, Chiba 277 8577, Japan
    Jpn J Cancer Res 92:220-30. 2001
    ..The dose of doxorubicin should be reduced to 40 mg / m(2), not because of the pharmacodynamic interaction between PSC-833 and doxorubicin affecting hematopoiesis, but because of pharmacokinetic interaction...
  10. ncbi Unexpected hepatotoxicities in patients with non-Hodgkin's lymphoma treated with irinotecan (CPT-11) and etoposide
    T Ohtsu
    Department of Medicine, National Cancer Center Hospital East, Chiba, Japan
    Jpn J Clin Oncol 28:502-6. 1998
    ....
  11. ncbi Acute myelogenous leukemia with monosomy 7, inv(3) (q21q26), involving activated EVI 1 gene occurring after a complete remission of lymphoblastic lymphoma: a case report
    T Igarashi
    Department of Medicine, National Cancer Center Hospital East, Chiba, Japan
    Jpn J Clin Oncol 28:688-95. 1998
    ....
  12. ncbi Successful treatment by radiation and hormone therapy of isolated local recurrence of breast cancer 24 years after mastectomy accompanied by immune thrombocytopenia: a case report
    T Igarashi
    Division of Oncology and Hematology, National Cancer Center Hospital East, Tokyo, Japan
    Jpn J Clin Oncol 28:270-5. 1998
    ..This may be the first case suggestive of a paraneoplastic syndrome of immune thrombocytopenia accompanied by local recurrence of breast cancer...
  13. ncbi Patients in phase I trials of anti-cancer agents in Japan: motivation, comprehension and expectations
    K Itoh
    Department of Medicine, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
    Br J Cancer 76:107-13. 1997
    ....
  14. ncbi Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group
    K Tobinai
    Department of Medical Oncology, National Cancer Center Hospital, Tokyo
    Ann Oncol 9:527-34. 1998
    ..The aim of the present trial was to determine whether or not this dose is practically applicable to Japanese patients with relapsed B-cell lymphoma with respect to safety, pharmacokinetics and efficacy...
  15. ncbi A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer
    K Muro
    Division of Gastrointestinal Oncology, National Cancer Center Hospital, Tokyo, Japan
    Ann Oncol 15:955-9. 2004
    ..To evaluate the activity and toxicity of docetaxel in patients with metastatic esophageal cancer...
  16. ncbi Phase III study to evaluate the use of high-dose chemotherapy as consolidation of treatment for high-risk postoperative breast cancer: Japan Clinical Oncology Group study, JCOG 9208
    Yutaka Tokuda
    Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa 259 1193, Japan
    Cancer Sci 99:145-51. 2008
    ..78). Although the prespecified values of the two arms were not so accurate as to allow detection of the observed difference, no advantage of HDC was observed in terms of RFS or overall survival...